October 24, 2011
FDA Approves Prezista Labeling That Includes 192-Week Data
The 192-week analysis showed that 70% of patients in the Prezista/ritonavir arm reached an undetectable viral load (<50copies/mL) vs. 61% of patients in the lopinavir/ritonavir arm. Virologic failure was 12% in the Prezista/ritonavir arm and 15% in the lopinavir/ritonavir arm. Statistical superiority of Prezista/ritonavir over the lopinavir/ritonavir regimen was demonstrated in both the intent-to-treat and on-protocol analysis.
For more information call (800) 526-7736 or visit www.prezista.com.